-+ 0.00%
-+ 0.00%
-+ 0.00%

Standard BioTools Completes Sale Of SomaLogic To Illumina For Up To $425M Plus Royalties

Benzinga·01/30/2026 14:14:50
Listen to the news

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy 

Continuing Operations on track to achieve positive adjusted EBITDA in 2026

BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina") for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggregate cash consideration of up to $425 million plus specified royalties.